Mar 27, 2026 · Eisai has submitted a new drug application seeking approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for Leqembi’s (lecanemab) subcutaneous …

Apr 22, 2024 · Eisai has agreed to a new deal with longtime Alzheimer’s disease partner BioArctic, signing up for a “research evaluation” of a preclinical drug designed to more effectively reach the …

Jul 19, 2015 · Anonymous discussion boards for pharmaceutical and biotech companies

Sep 1, 2025 · The US Food and Drug Administration (FDA) has approved a once-weekly autoinjector version of Eisai’s Alzheimer’s drug Leqembi (lecanemab), as the company seeks to grow the …

Jul 18, 2022 · Eisai’s oncology wing, H3 Biomedicine, is closing up shop for good, with the Japanese pharma saying that after 12 years, the work of the venture is “complete.”

Feb 27, 2025 · As part of a new strategic restructuring to streamline its American operations, Eisai plans to lay off approximately 121 employees across various U.S. functions, a company spokesperson told …

Mar 27, 2026 · Biopharma news today spans M&A, clinical wins and regulatory milestones, as companies push forward in gene therapy, obesity and chronic disease treatments. Novartis pens $2B …

Mar 27, 2026 · At the AD/PD annual meeting, Eisai presented real-world data suggesting Leqembi’s long-term safety and efficacy in people homozygous for APOE4, who were identified in trials as …

Dec 5, 2025 · Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief Clinical Officer Lynn Kramer expressed unwavering conviction in his …

Jun 9, 2025 · Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome Therapeutics. The New York City central nervous system …